Company Encyclopedia
View More
name
Freda
600223.SH
Lushang Freda Pharmaceutical Co.,Ltd. engages in the production and sales of pharmaceuticals, raw materials, and additives in China. The company is involved in cosmetics and medicine businesses. It provides cleansers, lotions, creams, essences, masks, and other products.
253.95 B
600223.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Personal Care ProductsIndustry
Industry Ranking17/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE5.18%C
    • Profit Margin5.67%C
    • Gross Margin49.75%B
  • Growth ScoreD
    • Revenue YoY-5.26%D
    • Net Profit YoY-9.47%C
    • Total Assets YoY-4.43%D
    • Net Assets YoY2.77%C
  • Cash ScoreC
    • Cash Flow Margin1763.99%B
    • OCF YoY-5.26%D
  • Operating ScoreB
    • Turnover0.63B
  • Debt ScoreA
    • Gearing Ratio16.16%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Sino Biological,Inc. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 511.45 million compared to CNY 464.95 million a year ago. Net income was CNY 110.18 million compared to CNY 99.32 million a year ago.Basic earnings per share from continuing operations was CNY 0.9058 compared to CNY 0.7787 a year ago.

    marketscreener·
    SZ
    301047
    +0.68%
    marketscreener·
    SZ
    301047
    +0.68%

    Lushang Freda Pharmaceutical to Divest Lushang Inzone Commercial Management Subsidiary for 88 Milion Yuan

    Lushang Freda Pharmaceutical to Divest Lushang Inzone Commercial Management Subsidiary for 88 Milion Yuan

    marketscreener·
    SH
    600223
    +1.22%
    marketscreener·
    SH
    600223
    +1.22%

    Rebuilding pharma’s credibility in the age of misinformation

    The episode of "The Top Line" features Dr. Freda Lewis-Hall discussing the fragile trust in the pharmaceutical industry amid rising misinformation. She emphasizes the importance of listening before messaging and explores how AI and omnichannel outreach can impact patient trust. Dr. Lewis-Hall advocates for rebuilding credibility through individual conversations, highlighting the need for industry-healthcare collaborations and the role of social media in restoring patient confidence.

    Fiercepharma·
    SH
    600223
    +1.22%
    Fiercepharma·
    SH
    600223
    +1.22%

    Freda: Net profit of 108 million yuan in the first half of 2025, a year-on-year decrease of 15.16%

    Freda announced that its operating revenue in the first half of 2025 was 1.79 billion yuan, a year-on-year decrease of 7.05%. Net profit was 108 million yuan, a year-on-year decrease of 15.16%

    Zhitong·
    SH
    600223
    +1.22%
    Zhitong·
    SH
    600223
    +1.22%

    Freda: Currently, it has not planned to make ergotamine its main product

    On August 8th, Freda stated on the interactive platform that the company is currently not planning to make ergotamine its main product

    Zhitong·
    SH
    600223
    +1.22%
    Zhitong·
    SH
    600223
    +1.22%
    © 2025 Longbridge｜Disclaimer